Smart cancer nanomedicine

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations

Life Sciences, Immunology, Oncology +17

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.9K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Medicine, Oncology, Pharmacology +17